메뉴 건너뛰기




Volumn 33, Issue 3, 2013, Pages 523-532

Pioglitazone attenuates valvular calcification induced by hypercholesterolemia

Author keywords

valvular vascular calcification; calcific aortic valve stenosis; echocardiography; hypercholesterolemia; peroxisome proliferator activated receptor

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN B100; CASPASE 3; GLUCOSE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN RECEPTOR; OSTEOCALCIN; PIOGLITAZONE; SERUM AMYLOID A;

EID: 84874388376     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300794     Document Type: Article
Times cited : (43)

References (60)
  • 1
    • 0027991976 scopus 로고
    • Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies
    • Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation. 1994;90:844-853.
    • (1994) Circulation , vol.90 , pp. 844-853
    • Otto, C.M.1    Kuusisto, J.2    Reichenbach, D.D.3    Gown, A.M.4    O'Brien, K.D.5
  • 5
    • 79952337610 scopus 로고    scopus 로고
    • Role of peroxisome proliferator-activated receptor-γ in atherosclerosis: An update
    • Wang N, Yin R, Liu Y, Mao G, Xi F. Role of peroxisome proliferator-activated receptor-γ in atherosclerosis: an update. Circ J. 2011;75:528-535.
    • (2011) Circ J , vol.75 , pp. 528-535
    • Wang, N.1    Yin, R.2    Liu, Y.3    Mao, G.4    Xi, F.5
  • 6
    • 83655167182 scopus 로고    scopus 로고
    • Disruption of endothelial peroxisome proliferator-activated receptor γ accelerates diet-induced atherogenesis in LDL receptor-null mice
    • Qu A, Shah YM, Manna SK, Gonzalez FJ. Disruption of endothelial peroxisome proliferator-activated receptor γ accelerates diet-induced atherogenesis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol. 2012;32:65-73.
    • (2012) Arterioscler Thromb Vasc Biol , vol.32 , pp. 65-73
    • Qu, A.1    Shah, Y.M.2    Manna, S.K.3    Gonzalez, F.J.4
  • 10
    • 33745839778 scopus 로고    scopus 로고
    • Transient suppression of PPARgamma directed ES cells into an osteoblastic lineage
    • Yamashita A, Takada T, Nemoto K, Yamamoto G, Torii R. Transient suppression of PPARgamma directed ES cells into an osteoblastic lineage. FEBS Lett. 2006;580:4121-4125.
    • (2006) FEBS Lett , vol.580 , pp. 4121-4125
    • Yamashita, A.1    Takada, T.2    Nemoto, K.3    Yamamoto, G.4    Torii, R.5
  • 11
    • 0035882483 scopus 로고    scopus 로고
    • Oxidative stress modulates osteoblastic differentiation of vascular and bone cells
    • Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med. 2001;31:509-519.
    • (2001) Free Radic Biol Med , vol.31 , pp. 509-519
    • Mody, N.1    Parhami, F.2    Sarafian, T.A.3    Demer, L.L.4
  • 13
    • 49849089138 scopus 로고    scopus 로고
    • Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans
    • Miller JD, Chu Y, Brooks RM, Richenbacher WE, Peña-Silva R, Heistad DD. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol. 2008;52:843-850.
    • (2008) J Am Coll Cardiol , vol.52 , pp. 843-850
    • Miller, J.D.1    Chu, Y.2    Brooks, R.M.3    Richenbacher, W.E.4    Peña-Silva, R.5    Heistad, D.D.6
  • 17
    • 0031886864 scopus 로고    scopus 로고
    • The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
    • Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
    • (1998) Nature , vol.391 , pp. 79-82
    • Ricote, M.1    Li, A.C.2    Willson, T.M.3    Kelly, C.J.4    Glass, C.K.5
  • 18
    • 33646524699 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptors and inflammation
    • Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther. 2006;110:371-385.
    • (2006) Pharmacol Ther , vol.110 , pp. 371-385
    • Moraes, L.A.1    Piqueras, L.2    Bishop-Bailey, D.3
  • 20
    • 79958147911 scopus 로고    scopus 로고
    • Calcific aortic valve stenosis: Methods, models, and mechanisms
    • Miller JD, Weiss RM, Heistad DD. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res. 2011;108:1392-1412.
    • (2011) Circ Res , vol.108 , pp. 1392-1412
    • Miller, J.D.1    Weiss, R.M.2    Heistad, D.D.3
  • 21
    • 79953232077 scopus 로고    scopus 로고
    • ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance
    • DeFronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104-1115.
    • (2011) N Engl J Med , vol.364 , pp. 1104-1115
    • Defronzo, R.A.1    Tripathy, D.2    Schwenke, D.C.3
  • 23
    • 0037314551 scopus 로고    scopus 로고
    • Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts
    • Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EA. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol. 2003;199:221-228.
    • (2003) J Pathol , vol.199 , pp. 221-228
    • Duan, W.R.1    Garner, D.S.2    Williams, S.D.3    Funckes-Shippy, C.L.4    Spath, I.S.5    Blomme, E.A.6
  • 25
    • 0036122331 scopus 로고    scopus 로고
    • Quantification of mRNA for endothelial NO synthase in mouse blood vessels by real-time polymerase chain reaction
    • Chu Y, Heistad DD, Knudtson KL, Lamping KG, Faraci FM. Quantification of mRNA for endothelial NO synthase in mouse blood vessels by real-time polymerase chain reaction. Arterioscler Thromb Vasc Biol. 2002;22:611-616.
    • (2002) Arterioscler Thromb Vasc Biol , vol.22 , pp. 611-616
    • Chu, Y.1    Heistad, D.D.2    Knudtson, K.L.3    Lamping, K.G.4    Faraci, F.M.5
  • 26
    • 33646417915 scopus 로고    scopus 로고
    • Serum amyloid A: The "other" inflammatory protein
    • O'Brien KD, Chait A. Serum amyloid A: the "other" inflammatory protein. Curr Atheroscler Rep. 2006;8:62-68.
    • (2006) Curr Atheroscler Rep , vol.8 , pp. 62-68
    • O'Brien, K.D.1    Chait, A.2
  • 27
    • 0032540325 scopus 로고    scopus 로고
    • Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma
    • Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998;93:229-240.
    • (1998) Cell , vol.93 , pp. 229-240
    • Nagy, L.1    Tontonoz, P.2    Alvarez, J.G.3    Chen, H.4    Evans, R.M.5
  • 28
    • 0032540012 scopus 로고    scopus 로고
    • PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
    • Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241-252.
    • (1998) Cell , vol.93 , pp. 241-252
    • Tontonoz, P.1    Nagy, L.2    Alvarez, J.G.3    Thomazy, V.A.4    Evans, R.M.5
  • 29
    • 0033864582 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
    • Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000;106:523-531.
    • (2000) J Clin Invest , vol.106 , pp. 523-531
    • Li, A.C.1    Brown, K.K.2    Silvestre, M.J.3    Willson, T.M.4    Palinski, W.5    Glass, C.K.6
  • 30
    • 67049159400 scopus 로고    scopus 로고
    • Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone
    • Nakaya H, Summers BD, Nicholson AC, Gotto AM Jr, Hajjar DP, Han J. Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone. Am J Pathol. 2009;174:2007-2014.
    • (2009) Am J Pathol , vol.174 , pp. 2007-2014
    • Nakaya, H.1    Summers, B.D.2    Nicholson, A.C.3    Gotto Jr., A.M.4    Hajjar, D.P.5    Han, J.6
  • 32
    • 67651123071 scopus 로고    scopus 로고
    • CD36-mediated cholesterol efflux is associated with PPARgamma activation via a MAPK-dependent COX-2 pathway in macrophages
    • Bujold K, Rhainds D, Jossart C, Febbraio M, Marleau S, Ong H. CD36-mediated cholesterol efflux is associated with PPARgamma activation via a MAPK-dependent COX-2 pathway in macrophages. Cardiovasc Res. 2009;83:457-464.
    • (2009) Cardiovasc Res , vol.83 , pp. 457-464
    • Bujold, K.1    Rhainds, D.2    Jossart, C.3    Febbraio, M.4    Marleau, S.5    Ong, H.6
  • 33
    • 0015156452 scopus 로고
    • Ultrastructural study of calcification of human aortic valve
    • Kim KM, Huang SN. Ultrastructural study of calcification of human aortic valve. Lab Invest. 1971;25:357-366.
    • (1971) Lab Invest , vol.25 , pp. 357-366
    • Kim, K.M.1    Huang, S.N.2
  • 34
    • 0034968385 scopus 로고    scopus 로고
    • Arterial calcification: A review of mechanisms, animal models, and the prospects for therapy
    • Wallin R, Wajih N, Greenwood GT, Sane DC. Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev. 2001;21:274-301.
    • (2001) Med Res Rev , vol.21 , pp. 274-301
    • Wallin, R.1    Wajih, N.2    Greenwood, G.T.3    Sane, D.C.4
  • 35
    • 0028903234 scopus 로고
    • Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques
    • Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest. 1995;95:2266-2274.
    • (1995) J Clin Invest , vol.95 , pp. 2266-2274
    • Bennett, M.R.1    Evan, G.I.2    Schwartz, S.M.3
  • 36
    • 0037314647 scopus 로고    scopus 로고
    • Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis
    • discussion 465
    • Jian B, Narula N, Li QY, Mohler ER III, Levy RJ. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg. 2003;75:457-465; discussion 465.
    • (2003) Ann Thorac Surg , vol.75 , pp. 457-465
    • Jian, B.1    Narula, N.2    Li, Q.Y.3    Mohler Iii, E.R.4    Levy, R.J.5
  • 37
    • 79955532876 scopus 로고    scopus 로고
    • Pioglitazone activates aortic telomerase and prevents stress-induced endothelial apoptosis
    • Werner C, Gensch C, Pöss J, Haendeler J, Böhm M, Laufs U. Pioglitazone activates aortic telomerase and prevents stress-induced endothelial apoptosis. Atherosclerosis. 2011;216:23-34.
    • (2011) Atherosclerosis , vol.216 , pp. 23-34
    • Werner, C.1    Gensch, C.2    Pöss, J.3    Haendeler, J.4    Böhm, M.5    Laufs, U.6
  • 38
    • 0035182469 scopus 로고    scopus 로고
    • Time course of osteopontin, osteocalcin, and osteonectin accumulation and calcification after acute vessel wall injury
    • Gadeau AP, Chaulet H, Daret D, Kockx M, Daniel-Lamazière JM, Desgranges C. Time course of osteopontin, osteocalcin, and osteonectin accumulation and calcification after acute vessel wall injury. J Histochem Cytochem. 2001;49:79-86.
    • (2001) J Histochem Cytochem , vol.49 , pp. 79-86
    • Gadeau, A.P.1    Chaulet, H.2    Daret, D.3    Kockx, M.4    Daniel-Lamazière, J.M.5    Desgranges, C.6
  • 39
    • 35848933241 scopus 로고    scopus 로고
    • Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice
    • Thorp E, Kuriakose G, Shah YM, Gonzalez FJ, Tabas I. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice. Circulation. 2007;116:2182-2190.
    • (2007) Circulation , vol.116 , pp. 2182-2190
    • Thorp, E.1    Kuriakose, G.2    Shah, Y.M.3    Gonzalez, F.J.4    Tabas, I.5
  • 41
    • 79955034448 scopus 로고    scopus 로고
    • Transcriptional regulation of bone formation
    • Baek WY, Kim JE. Transcriptional regulation of bone formation. Front Biosci (Schol Ed). 2011;3:126-135.
    • (2011) Front Biosci (Schol Ed) , vol.3 , pp. 126-135
    • Baek, W.Y.1    Kim, J.E.2
  • 42
    • 17644380642 scopus 로고    scopus 로고
    • Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves
    • Simmons CA, Grant GR, Manduchi E, Davies PF. Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res. 2005;96:792-799.
    • (2005) Circ Res , vol.96 , pp. 792-799
    • Simmons, C.A.1    Grant, G.R.2    Manduchi, E.3    Davies, P.F.4
  • 43
    • 75149144852 scopus 로고    scopus 로고
    • Hypercholesterolemia induces side-specific phenotypic changes and peroxisome proliferator-activated receptor-gamma pathway activation in swine aortic valve endothelium
    • Guerraty MA, Grant GR, Karanian JW, Chiesa OA, Pritchard WF, Davies PF. Hypercholesterolemia induces side-specific phenotypic changes and peroxisome proliferator-activated receptor-gamma pathway activation in swine aortic valve endothelium. Arterioscler Thromb Vasc Biol. 2010;30:225-231.
    • (2010) Arterioscler Thromb Vasc Biol , vol.30 , pp. 225-231
    • Guerraty, M.A.1    Grant, G.R.2    Karanian, J.W.3    Chiesa, O.A.4    Pritchard, W.F.5    Davies, P.F.6
  • 44
    • 80052329754 scopus 로고    scopus 로고
    • Discovery of shear-and side-specific mRNAs and miRNAs in human aortic valvular endothelial cells
    • Holliday CJ, Ankeny RF, Jo H, Nerem RM. Discovery of shear-and side-specific mRNAs and miRNAs in human aortic valvular endothelial cells. Am J Physiol Heart Circ Physiol. 2011;301:H856-H867.
    • (2011) Am J Physiol Heart Circ Physiol , vol.301
    • Holliday, C.J.1    Ankeny, R.F.2    Jo, H.3    Nerem, R.M.4
  • 45
    • 0024370924 scopus 로고
    • Osteocalcin and matrix Gla protein: Vitamin K-dependent proteins in bone
    • Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev. 1989;69:990-1047.
    • (1989) Physiol Rev , vol.69 , pp. 990-1047
    • Hauschka, P.V.1    Lian, J.B.2    Cole, D.E.3    Gundberg, C.M.4
  • 47
    • 21044437380 scopus 로고    scopus 로고
    • Spectrum of calcific aortic valve disease: Pathogenesis, disease progression, and treatment strategies
    • Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005;111:3316-3326.
    • (2005) Circulation , vol.111 , pp. 3316-3326
    • Freeman, R.V.1    Otto, C.M.2
  • 48
    • 20344364674 scopus 로고    scopus 로고
    • Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis
    • Scottish Aortic Stenosis Lipid Lowering Trial
    • Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389-2397.
    • (2005) N Engl J Med , vol.352 , pp. 2389-2397
    • Cowell, S.J.1    Newby, D.E.2    Prescott, R.J.3    Bloomfield, P.4    Reid, J.5    Northridge, D.B.6    Boon, N.A.7
  • 49
    • 52649120889 scopus 로고    scopus 로고
    • SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis
    • Rossebø AB, Pedersen TR, Boman K, et al.; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-1356.
    • (2008) N Engl J Med , vol.359 , pp. 1343-1356
    • Rossebø, A.B.1    Pedersen, T.R.2    Boman, K.3
  • 50
    • 74949091630 scopus 로고    scopus 로고
    • ASTRONOMER Investigators Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: Results of the aortic stenosis progression observation: Measuring effects of rosuvastatin (ASTRONOMER) trial
    • Chan KL, Teo K, Dumesnil JG, Ni A, Tam J; ASTRONOMER Investigators. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306-314.
    • (2010) Circulation , vol.121 , pp. 306-314
    • Chan, K.L.1    Teo, K.2    Dumesnil, J.G.3    Ni, A.4    Tam, J.5
  • 51
    • 14044262240 scopus 로고    scopus 로고
    • Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation
    • Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation. 2005;111:920-925.
    • (2005) Circulation , vol.111 , pp. 920-925
    • Roberts, W.C.1    Ko, J.M.2
  • 52
  • 53
    • 84855405202 scopus 로고    scopus 로고
    • A second chance for a PPARγ targeted therapy?
    • Norris AW, Sigmund CD. A second chance for a PPARγ targeted therapy? Circ Res. 2012;110:8-11.
    • (2012) Circ Res , vol.110 , pp. 8-11
    • Norris, A.W.1    Sigmund, C.D.2
  • 54
    • 34648832073 scopus 로고    scopus 로고
    • Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials
    • Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129-1136.
    • (2007) Lancet , vol.370 , pp. 1129-1136
    • Lago, R.M.1    Singh, P.P.2    Nesto, R.W.3
  • 55
    • 0036833805 scopus 로고    scopus 로고
    • A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes
    • St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, Patel J, Freed M. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002;25:2058-2064.
    • (2002) Diabetes Care , vol.25 , pp. 2058-2064
    • St John Sutton, M.1    Rendell, M.2    Dandona, P.3    Dole, J.F.4    Murphy, K.5    Patwardhan, R.6    Patel, J.7    Freed, M.8
  • 56
    • 34548580881 scopus 로고    scopus 로고
    • Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis
    • Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298:1189-1195.
    • (2007) JAMA , vol.298 , pp. 1189-1195
    • Singh, S.1    Loke, Y.K.2    Furberg, C.D.3
  • 57
    • 77951601655 scopus 로고    scopus 로고
    • Thiazolidinedione drugs and cardiovascular risks: A science advisory from the American Heart Association and American College of Cardiology Foundation
    • Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation. 2010;121:1868-1877.
    • (2010) Circulation , vol.121 , pp. 1868-1877
    • Kaul, S.1    Bolger, A.F.2    Herrington, D.3    Giugliano, R.P.4    Eckel, R.H.5
  • 58
    • 26244453309 scopus 로고    scopus 로고
    • PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial
    • Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
    • (2005) Lancet , vol.366 , pp. 1279-1289
    • Dormandy, J.A.1    Charbonnel, B.2    Eckland, D.J.3
  • 59
    • 33847675510 scopus 로고    scopus 로고
    • PROactive Investigators the effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) Study
    • Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007;49:1772-1780.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 1772-1780
    • Erdmann, E.1    Dormandy, J.A.2    Charbonnel, B.3    Massi-Benedetti, M.4    Moules, I.K.5    Skene, A.M.6
  • 60
    • 77954988618 scopus 로고    scopus 로고
    • Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone
    • Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411-418.
    • (2010) JAMA , vol.304 , pp. 411-418
    • Graham, D.J.1    Ouellet-Hellstrom, R.2    MacUrdy, T.E.3    Ali, F.4    Sholley, C.5    Worrall, C.6    Kelman, J.A.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.